Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Objective is to Examine the Effectiveness of Ai Integrated Proactive Thought Control for Social Anxiety Disorder and Compare Its Effectiveness With Active Control Group and Cognitive Behavioral Therapy. Participants With SAD Will be Recruited From Educational Setting, Will Get 8 Therapy Sessions.

NCT07810348 is registered in ClinicalTrials.gov with Farah Shahzadi as lead sponsor.

NCT NCT07810348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07810348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Objective is to Examine the Effectiveness of Ai Integrated Proactive Thought Control for Social Anxiety Disorder and Compare Its Effectiveness With Active Control Group and Cognitive Behavioral Therapy. Participants With SAD Will be Recruited From Educational Setting, Will Get 8 Therapy Sessions.
Lead sponsor
Farah Shahzadi
Phase
Not applicable
Overall status
Completed
Start date
March 14, 2026
Completion date
August 14, 2026
Enrollment
75 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

social anxiety disorder (sad)